This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Today's Health Winners and Losers

Shares of Bausch & Lomb (BOL) were among the worst-performing health-related stocks Tuesday, slumping 17% after the eye-care company halted U.S. shipments of its ReNu with MoistureLoc contact-lens solution because of reports of fungal infections in contact lens wearers.

The suspension follows the release of a report by the U.S. Centers for Disease Control and Prevention that it is reviewing some 109 cases of suspected fungal keratitis, a rare infection that can cause vision loss. "The CDC data released today are both troubling and perplexing, as there is an apparent disproportionate representation of U.S. manufactured ReNu with MoistureLoc in the underlying data," Bausch & Lomb said.

Still, the company said that based on extensive testing, analysis and further internal reviews, "the available scientific evidence does not establish any type of ReNu solution as the cause."

The CDC has so far only reviewed 30 of the 109 cases, but 28 involved contact-lens wearers, Bausch & Lomb said. Of those 28 cases, 21 reported using ReNu contact-lens care products, while another five reported using a combination of ReNu and products made by other companies. Shares were trading down $9.85 to $47.59.

Alcon (ACL), a rival that could benefit from Bausch & Lomb's troubles, saw its shares rise $3 to $104.22, while shares of another competitor, Advanced Medical Optics (EYE), jumped $1.95 to $47.42.

Immucor (BLUD) rose 4% after the company announced a 3-for-2 stock split. The company, which sells reagents and systems used to identify the properties of blood, expects to distribute the shares May 15 to shareholders of record on April 24.

"We have experienced a consistent rise in the value of our stock as a result of the success of the Galileo and our continuing success in improving both gross and operating margins," the company said. "This stock split is a result of the success of these strategies." The stock split marks the eighth one for the company since going public in 1985.

Immucor shares, which have climbed about 35% since the last stock split in 2004, recently were up $1.10 to $31.09.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
GIVN $0.00 0.00%
BSX $16.56 -2.40%
PRSC $44.56 -0.98%
AAPL $126.75 0.27%
FB $80.01 -1.50%

Markets

DOW 17,856.78 -278.94 -1.54%
S&P 500 2,071.26 -29.78 -1.42%
NASDAQ 4,927.37 -55.4390 -1.11%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs